FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Retains Buy Rating On Shares Of Abbvie Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our target at $255, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.1x, justified by its improving long-term growth prospects. We raise our 2026 EPS view to $14.17 from $14.02 to reflect the Q1 beat and raised expectations for the rest of the year. We keep our 2027 EPS view at $16.13. ABBV reported a strong start to 2026, with Q1 results surpassing expectations. Revenues reached $15B, a 12.4% increase, beating expectations due to the continued momentum in the Immunology and Neuroscience franchises. Adjusted EPS came in at $2.65, above the guidance midpoint despite an unfavorable impact from acquired IPR&D. We think the early data from the Amylin Analog (ABBV-295) showed promising weight loss results with good tolerability. With Phase 2 studies expected to begin in Q3 2026, we think updates should be closely followed as ABBV-295 could well position AbbVie in the highly lucrative obesity market with a potentially differentiated, non-incretin-based mechanism.

Related Articles

Research

Research Alert: CFRA Lifts Rating On Shares Of Parker-hannifin To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following the recent pullback in shares and encouraging Q3 FY 26 (Jun.) results, we lift our 12-month target by $50 to $1,050 and upgrade our view on shares to Buy from Hold. We value shares at 30.5x our FY 27 EPS outlook of $34.42 (up from $33.35; FY 26 EPS view revised to $31.20 from $30.90), above the company's long-term multiple average given an accelerated growth trajectory within aerospace markets. PH's Diversified Industrial business is beginning to inflect into recovery, with orders above 7% in NA signaling a cyclical uptrend. Q3 structural improvements in margins inform our upgraded outlook for earnings in FY 26-FY 27, with negative mix impacts from outsized growth in lower-margin OEM products being more than offset by strong operational execution. With greater participation in growth across the portfolio, PH once again deploying capital to synergistic M&A, and margin expansion still in full swing, we believe that shares are positioned to outperform over the next 12 months.

$PH
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Chipotle Mexican Grill Inc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price at $44, 35x our 2026 EPS estimate, a discount to shares' 50x five-year average, reflecting a lower comparable sales growth profile. We raise our 2026 EPS estimate to $1.26 (from $1.25) and lower 2027's to $1.45 (from $1.46). Following encouraging Q1 results, we reiterate our Buy opinion. CMG posted comparable sales growth of 0.5%, including transaction growth of 0.6%, which highlights the company's focus on value perception with U.S. consumers. We are encouraged by comparable sales growth stabilization following declines in 2025, suggesting the company's structural growth profile remains intact. Further evidence of structural growth catalysts includes new store growth (+49 in Q1) and a pipeline of limited-time offerings and incremental add-ons (such as its cilantro lime sauce) gaining traction and boosting revenue without increasing menu prices. Though this strategy will pressure restaurant margins (-250 bps in Q1), we think this is beneficial for long-term growth.

$CMG
Research

Research Alert: CFRA Maintains Sell Rating On Shares Of Mid-america Apartment Communities, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price by $6 to $119, recognizing weakness in MAA's key rental markets and a forward P/FFO of 14.0x compared to the multifamily residential REIT average at 15.5x. We raise our FFO estimate in 2026 by $0.15 to $8.50 and lower 2027 by $0.10 to $8.70 per share on total rental revenue of $2.2B and $2.3B, respectively. We have a more cautious FFO outlook for 2027 on our view that raising rents on new leases will be challenging, as it has been in 2026. MAA's geographic footprint in mostly Sun Belt markets faces new supply that has put downward pressure on monthly lease rates and sparked the need for incentives on new tenant leases to meet absorption and reduce vacancies. We do not think the U.S. economy and employment trends are likely to be a catalyst for higher monthly rental rates or revenue. Some of MAA's major Sun Belt markets realized cash NOI declines, like Denver (-13% Y/Y) and Austin, TX (-9% Y/Y), with weakness in other local markets. Dividend yield is 4.7%, which we think is secure.

$MAA